# CagriSema Under FDA Review: What Amylin Plus GLP-1 Means in 2026
> Disclaimer: PeptIQ is not a medical provider. This article is educational only and does not provide medical advice. CagriSema and cagrilintide are investigational in the United States as of September 2, 2026. Do not use a research or compounded product as a substitute for an FDA-approved medicine.
CagriSema is under FDA review.
Novo Nordisk submitted a New Drug Application on December 18, 2025 for chronic weight management in eligible adults. The proposed once-weekly injection combines cagrilintide 2.4 mg, a long-acting amylin analogue, with semaglutide 2.4 mg, a GLP-1 receptor agonist.
As of September 2, 2026, FDA has not approved the combination. Novo has said it expects an FDA decision in 2026, but no public source has confirmed an exact FDA action date. A submitted application is a request for approval, not a guarantee.
CagriSema also gets grouped with every new multi-hormone medicine in development. That blurs an important difference. It combines two separate analogues with two receptor systems. A triagonist is one molecule engineered to activate three receptor systems.
What is in CagriSema
The name combines parts of the two active ingredients:
- Cagri refers to cagrilintide, a long-acting amylin analogue.
- Sema refers to semaglutide, an established GLP-1 receptor agonist.
Novo designed the product as a fixed-dose combination delivered once weekly. If approved as submitted, it would be the first injectable combination of a GLP-1 receptor agonist and an amylin analogue for this use.
Semaglutide has FDA-approved products. Cagrilintide does not have a standalone FDA approval. Putting semaglutide into the combination does not make CagriSema approved before FDA finishes reviewing its formulation, clinical data, manufacturing, and label.
What amylin does
Amylin is a hormone released by pancreatic beta cells alongside insulin after eating. It helps regulate signals involved in satiety, food intake, and the movement of food through the stomach. Native amylin does not make a convenient once-weekly medicine, so drug developers create analogues with properties suited to longer action.
Cagrilintide is designed to act on amylin receptors over an extended period. Its role in CagriSema is not to copy GLP-1. It adds a second signaling route.
The combination can also create overlapping tolerability problems. Gastrointestinal effects are an important part of FDA's review. A plausible mechanism is not enough. FDA must decide whether the fixed combination's benefits outweigh its risks at the proposed doses.
How the GLP-1 side works
Semaglutide activates GLP-1 receptors. In approved uses, this receptor activity affects glucose-dependent insulin secretion, glucagon signaling, gastric emptying, and appetite regulation.
Semaglutide brings a large clinical history to the application, but CagriSema still needs its own evidence. The formulation, titration, exposure, and adverse effects are specific to the combination.
Patients should not assume that experience with a semaglutide product predicts exactly how they would respond to CagriSema. The added amylin pathway changes the intervention.
Why CagriSema is not a triagonist
A triagonist such as investigational retatrutide uses one engineered molecule to activate three receptors. Retatrutide targets GIP, GLP-1, and glucagon receptors.
CagriSema uses two molecules:
- Cagrilintide acts through amylin receptors.
- Semaglutide acts through GLP-1 receptors.
The difference affects development and interpretation. With a fixed combination, researchers can study the contribution of each component and compare the pair against individual ingredients. The formulation has to keep both active ingredients stable and deliver the intended doses together.
With a single triagonist, the balance of activity across three receptors is built into one molecule. Developers tune that receptor profile during design and then manufacture one active drug substance.
Counting receptors does not rank these products. What matters is the clinical result, adverse-event burden, dosing practicality, and manufacturing consistency.
What the FDA is reviewing
FDA does not publish every question exchanged with a sponsor during an active review. The application itself gives us a reasonable map of the work.
The agency will examine:
- pivotal efficacy results and how missing data were handled
- adverse events, serious events, and treatment discontinuations
- the contribution of cagrilintide and semaglutide to the combination
- the proposed dose-escalation schedule
- manufacturing consistency and stability of the co-formulation
- the injection device and instructions for use
- warnings, contraindications, and post-approval commitments
FDA must also decide whether the fixed ratio is appropriate for patients who may respond to the two components differently. A fixed product offers less freedom to adjust each ingredient.
FDA may approve the application, request more information, require label changes, or issue a complete response letter. Until the agency acts, predictions are still predictions.
What the clinical data can and cannot tell us
Novo's application relies on the REDEFINE clinical program. FDA will look beyond topline results at dose completion, treatment discontinuations, adverse effects during escalation, missing data, and comparisons with semaglutide alone.
One head-to-head comparison cannot answer every clinical question. Trial populations, titration rules, and statistical assumptions shape the result. Claims that CagriSema is already "better" than every approved option run ahead of the review.
What clinics should track during review
Clinics do not need to speculate about a precise approval day. They need to watch for verifiable milestones.
First, watch for an FDA decision or a sponsor announcement that clearly states the outcome. An expected quarter is not an action date.
Second, read the final label if the product is approved. The approved indication, starting dose, escalation schedule, contraindications, warnings, and missed-dose instructions will control clinical use.
Third, watch the manufacturing and launch plan. Approval and pharmacy availability may not happen at the same time. Device supply, production capacity, payer contracts, and distribution can shape access.
Fourth, look for the full clinical publications and FDA review documents. FDA often posts multidisciplinary reviews after an approval. Those documents show how reviewers handled uncertainty in a way a launch announcement cannot.
Fifth, check whether FDA requires postmarketing studies or additional safety monitoring. Those requirements reveal where uncertainty remains.
No current shortcut through research products
CagriSema is a specific fixed-dose product submitted by Novo Nordisk. Combining materials labeled cagrilintide and semaglutide does not recreate it. Identity, concentration, impurities, sterility, stability, and dose ratio all matter.
The same warning applies to standalone cagrilintide sold through research channels. Clinics should keep current care tied to approved products. If CagriSema receives approval, its FDA label will define the legitimate route.
The bottom line
CagriSema combines two established biological ideas in one weekly product: amylin receptor activity from cagrilintide and GLP-1 receptor activity from semaglutide.
That makes it different from a triagonist. CagriSema is a two-molecule fixed combination acting through two receptor systems. A triagonist uses one molecule to activate three.
Novo submitted the U.S. application in December 2025. As of September 2, 2026, the combination remains under review and is not FDA-approved. The next useful information will come from FDA's decision, the final label if approved, and the detailed review record.
Source: Novo Nordisk's December 18, 2025 CagriSema filing announcement.
Frequently Asked Questions
Q: Is CagriSema FDA-approved as of September 2, 2026?
A: No. Novo Nordisk submitted the application in December 2025, and FDA review remains underway.
Q: What two medicines are in CagriSema?
A: It combines cagrilintide 2.4 mg, a long-acting amylin analogue, with semaglutide 2.4 mg, a GLP-1 receptor agonist.
Q: Is CagriSema a triagonist?
A: No. It is a fixed combination of two molecules acting through amylin and GLP-1 receptor systems. A triagonist is one molecule designed to activate three receptor systems.
Q: Has FDA announced an exact decision date?
A: No exact public FDA action date has been confirmed. Novo has said it expects a decision in 2026, but the timing and outcome remain subject to FDA review.
Q: Can a pharmacy or research seller recreate CagriSema now?
A: A product using the same ingredient names should not be treated as equivalent to Novo's submitted formulation. Identity, purity, sterility, stability, dose ratio, and delivery controls all matter.
Q: What should clinics read if FDA approves it?
A: Start with the FDA-approved label, prescribing information, instructions for use, and FDA review documents. Those sources define the approved use and explain the agency's safety and efficacy conclusions.
